Nicholas Jacobus

Craig Thompson, CEO of Cerevance touches on the NETSseq platform and how it shapes Cerevance's approach to the drug discovery strategy.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global stock exchange listings, and reports that President Trump will announce a government-run direct-to-patient drug purchasing website.

Kedrion Biopharma celebrates FDA approval of Qivigy, enhancing treatment options for primary immunodeficiency while committing to significant U.S. investments.

Novo Nordisk aims to revolutionize diabetes care with Awiqli, a potential once-weekly insulin, resubmitted for FDA approval after addressing previous concerns.

Craig Thompson, CEO of Cerevance discusses the key scientific and clinical insights that lead to Cerevance's pursuit of Solengepras.

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia.

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like Petosemtamab for cancer treatment.

GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.

In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the FDA’s approval of Eli Lilly’s Inluriyo for ESR1-mutated metastatic breast cancer, and President Trump’s call for steep tariffs on branded pharmaceuticals.

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient care and outcomes.

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing a critical health need.

In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony Biosciences’ trial setback for Zygel, and the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations.

Ascletis Pharma reveals ASC47, a promising weight loss drug, shows over 56% greater body weight reduction when combined with semaglutide in obesity treatment.

Pharma leaders embrace direct-to-consumer strategies, with 94% exploring DTC programs to enhance patient experience and accelerate treatment access.

In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.

CDC vaccine advisors shift to shared decision-making for Covid-19 vaccines, emphasizing patient-provider consultations amid insurance concerns.

Harmony Biosciences reveals disappointing results from the Phase III Reconnect study of ZYN002 for Fragile X Syndrome, highlighting ongoing research challenges.

Glenmark partners with Hengrui Pharma to develop Trastuzumab Rezetecan, enhancing its oncology pipeline and addressing unmet cancer treatment needs.

Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on changing the treatment paradigm for obesity & MACE indications, important considerations for translating cardiovascular benefits in injectable GLP-1s, and clinical potential for oral GLP-1s.

In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to President Trump’s claims linking Tylenol use to autism risk.

GSK seeks FDA approval for Leucovorin to treat cerebral folate deficiency and autism symptoms, promising new hope for affected children.

Scholar Rock navigates FDA's Complete Response Letter for Apitegromab, aiming for swift resubmission to address spinal muscular atrophy treatment needs.

Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and the clinical and scientific hurdles oral GLP-1 formulations need to overcome to gain comparable traction.

Rob DeWig, VP of Healthcare Sales at Inmar, touched on the current operational challenges that health system pharmacies face.

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

FDA denies approval for Rexulti in PTSD treatment, citing insufficient evidence despite clinical trials. Otsuka and Lundbeck plan next steps.

Pfizer acquires Metsera for $4.9 billion, enhancing its portfolio in obesity and cardiovascular treatments with innovative therapies and strong clinical potential.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims change for Premier Members.

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and chickenpox amid safety concerns.